Postsurgical immunity is prevented by CD4+CD25+ Treg cells and mediated by CD8 T cells. A, basic schematic outline of experiments: mice received primary B16 tumors in the right flank on day 0, anti-CD4 treatment on days 4 and 10, and surgery to remove primary tumors on day 12. Growth of challenge tumors. B, mice received treatments as specified in the figure and challenge tumors were given in the left flank 1 day after surgery. Anti-CD8 was also given in one group on days −2, +5, and +12 relative to the challenge tumor. C, mice received treatments as specified in the figure and challenge tumors were given in the left flank 1 d after surgery. Indicated groups also received anti-CD25 treatment on day −4 relative to the primary tumor. D, mice received treatments as specified below each bar, and challenge tumors were injected i.v. either 1 d following surgery (left) or 6 d before surgery (right). These mice were sacrificed ~22 d following challenge and pigmented surface lung metastases were counted. A to D, each experiment involved 10 to 16 mice per group and was conducted at least twice with similar results. Statistical significance was determined by log-rank analysis (B and C) or two-tailed Student’s t test (D). D, columns, average; bars, SD. NS, no significance (P > 0.05).